Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrest

Cell Death and Differentiation

Volumn 17, Issue 9, 2010, Pages 1511-1523

  Chan, Q K Y ^a   Lam, H M ^b   Ng, C F ^c   Lee, A Y Y ^a   Chan, E S Y ^c   Ng, H K ^a,c   Ho, S M ^b   Lau, K M ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

1 4 (6 bromobenzo 1,3 dioxol 5yl) 3a,4,5,9b tetrahydro 3H cyclopenta c quinolin 8 yl ethanone; G; G protein coupled receptor 30; G2 M; non genomic estrogen signaling; signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CELL PROTEIN; CYCLIN A2; CYCLIN B2; G PROTEIN COUPLED RECEPTOR 30; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C FOS; PROTEIN C JUN; PROTEIN CDC2; PROTEIN CDC25C; PROTEIN P21; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOPENTANES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; G2 PHASE; GENE EXPRESSION; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; QUINOLINES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77955711650     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.20     Document Type: Article

References (40)

1. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006; 147: 5557-5563.
2. Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev 2007; 28: 726-741.
3. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002; 16: 938-946.
4. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006; 20: 1996-2009.
5. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-a, hER-a36: transduction of estrogen-and antiestrogen- dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 2006; 103: 9063-9068.
6. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146: 624-632.
7. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 2006; 70: 1414-1423.
8. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 631-646.
9. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007; 67: 1859-1866.
10. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol 2008; 109: 350-353.
11. Teng J, Wang ZY, Prossnitz ER, Bjorling DE. The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 2008; 149: 4024-4034.
12. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D et al. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008; 149: 4846-4856.
13. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006; 2: 207-212.
14. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004; 279: 27008-27016.
15. Ke N, Albers A, Claassen G, Yu DH, Chatterton JE, Hu X et al. One-week 96-well soft agar growth assay for cancer target validation. Biotechniques 2004; 36: 826-833.
16. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
17. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-362.
18. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000; 60: 3175-3182.
19. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH et al. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999; 274: 29677-29682.
20. Yun J, Chae HD, Choi TS, Kim EH, Bang YJ, Chung J et al. Cdk2-dependent phosphorylation of the NF-Y transcription factor and its involvement in the p53-p21 signaling pathway. J Biol Chem 2003; 278: 36966-36972.
21. Lenormand P, Pagès G, Sardet C, L'Allemain G, Meloche S, Pouysségur J. MAP kinases: activation, subcellular localization and role in the control of cell proliferation. Adv Second Messenger Phosphoprotein Res 1993; 28: 237-244.
22. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-157.
23. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 1988; 55: 875-885.
24. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature 1991; 353: 670-674.
25. Gupta P, Prywes R. ATF1 phosphorylation by the ERK1/2 MAPK pathway is required for epidermal growth factor-induced c-jun expression. J Biol Chem 2002; 277: 50550-50556.
26. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, Lo Castro M et al. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 1994; 54: 1190-1193.
27. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009; 28: 523-532.
28. Haas E, Bhattacharya I, Brailoiu E, Damjanović M, Brailoiu GC, Gao X et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 2009; 104: 288-291.
29. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-185.
30. Stanciu M, DeFranco DB. Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J Biol Chem 2002; 277: 4010-4017.
31. Adachi T, Kar S, Wang M, Carr BI. Transient and sustained ERK1/2 phosphorylation and nuclear translocation in growth control. J Cell Physiol 2002; 192: 151-159.
32. Chen JR, Plotkin LI, Aguirre JI, Han L, Jilka RL, Kousteni S et al. Transient versus sustained phosphorylation and nuclear accumulation of ERK1/2s underlie anti-versus proapoptotic effects of estrogens. J Biol Chem 2005; 280: 4632-4638.
33. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008; 10: e19.
34. Dulić V, Stein GH, Far DF, Reed SI. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 1998; 18: 546-557.
35. Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 1997; 94: 448-452.
36. Dangi S, Chen FM, Shapiro P. Activation of extracellular signal-regulated kinase (ERK1/2) in G2 phase delays mitotic entry through p21(WAF1/CIP1)CIP1. Cell Prolif 2006; 39: 261-279.
37. Prasad S, Kaur J, Roy P, Kalra N, Shukla Y. Theaflavins induce G2/M arrest by modulating expression of p21(WAF1/CIP1)waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells. Life Sci 2007; 81: 1323-1331.
38. Manni I, Mazzaro G, Gurtner A, Mantovani R, Haugwitz U, Krause K et al. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem 2001; 276: 5570-5576.
39. Hu Q, Lu JF, Luo R, Sen S, Maity SN. Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res 2006; 34: 6272-6785.
40. Kardassis D, Papakosta P, Pardali K, Moustakas A. c-Jun transactivates the promoter of the human p21 gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem 1999; 274: 29572-29581.